Advances in the treatment of non-small cell lung cancer: focus on anti-PD-1/PD-L1 antibody

VernacularTitle:抗PD-1/PD-L1单抗治疗非小细胞肺癌的研究进展
Author: Changcheng ZHANG ; Xiaoyan KANG ; Liyan QU ; Xia SONG
Keywords: Membrane glycoproteins/TU; Antibodies,monoclonal/TU; Carcinoma,non-small-cell lung/TH; Immunotherapy; Review
From: Journal of Chinese Physician 2017;19(8):1275-1278
CountryChina
Language:Chinese
Abstract: Immunotherapy is revolutionizing the treatment of non-small cell lung cancer (NSCLC).Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies have recently led to significant and durable improvements in the clinical outcome of NSCLC,and the anti-PD-1 antibody has been approved to use in first-line and second-line treatment of NSCLC.However,there are still many problems to be solved.The role of PD-L1 as a predictive biomarker remains unclear.Combination treatment models are being explored.This review summarizes the clinical efficacy,drug adverse reaction,combined treatment,and potential immune biomarkers of anti-PD-1/PD-L1 antibody research progress in the treatment of NSCLC.